It requires either mutated oncogene chimeric nucleophosmin/anaplastic lymphoma kinase (ALK) in T-cell lymphoma [173], Latent membrane protein-1 (LMP1) of Epstein–Barr virus in nasopharyngeal carcinoma [174], HDAC6 in osteosarcoma [175], NF-κB in melanoma [176] or HIF-1α in pulmonary adenocarcinoma [177]. This evidence concerns the gene ALK and melanoma.